NEW YORK (GenomeWeb) – NeoGenomics today announced it has entered into a research agreement with Northwestern University's Robert H. Lurie Comprehensive Cancer Center and the Northwestern Medicine Developmental Therapeutics Institute. The partners will start a large translational program to establish the clinical utility of comprehensive genomic profiling technologies throughout the development of cancer therapies.
Research will focus on individualized patient care and will include a broad range of studies to expand current protocols focused on matching tumor genome profiles identified by the firm's NeoType cancer profiling tests with investigational therapies.
"We need to perform appropriate molecular analyses on all possible patient tumors. NeoGenomics is a key ally in NMDTI's focus on individualized patient care with cognate therapies directed at key molecular targets in cancer," NMDTI Director Francis Giles said in a statement.
"Working with NMDTI, we will explore how our NeoType cancer profiles can help guide clinicians in selecting the precise therapeutic approach for treating specific cancers in order to improve outcomes," NeoGenomics Chief Medical Officer Maher Albitar said.
In November, the Lurie Cancer Center and NMDTI signed a research agreement with Foundation Medicine to develop cancer profiling technologies.
Financial and other details of the agreement were not disclosed.